The cellular prion protein (PrPc) is a sialoglycoprotein involved in the pathogenesis of prion diseases. It has been identified at the plasma membrane of several cell types. All-trans retinoic acid (ATRA) is known to induce differentiation of human leukemia cell lines in vitro. PrPc messenger ribonucleic acid (mRNA) and protein are down-regulated upon ATRA-induced differentiation of HL60 cells. In this report, we have investigated the regulation of PrPc mRNA and protein expression during ATRAtreatment of maturation-sensitive (NB4) and -resistant (NB4-R1 and NB4-R2) cell lines. In ATRA-induced maturation of NB4 cells, down-regulation of PrPc mRNA and protein were observed. We also show that down-regulation of PrPc mRNA is dependent on protein synthesis. Moreover, the same downregulation of prion protein by ATRA was observed at the surface of maturation-resistant, ATRA-responsive NB4-R1 cells. In contrast, the maturation-resistant and ATRA-unresponsive NB4-R2 subline showed no variation in membrane prion protein expression. These results demonstrate a dissociation between the regulation of prion protein expression by ATRA and the process of granulocyte maturation. We propose that retinoids should be investigated further as a preventive strategy to slow down prion disease progression. Leukemia (2002) 16, 940-948.
Introduction
The prion diseases or transmissible spongiform encephalopathies (TSE) are a group of neurodegenerative disorders of animals and humans. They include scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle, Creutzfeldt-Jakob disease (CJD) in humans. These diseases are characterized by the accumulation in the central nervous system (CNS) of an abnormal protein designated PrPsc (scrapie prion protein). This pathogenic form is derived, by a posttranslational conformational modification, from the cellular prion protein or PrPc which is a host-encoded protein. [1] [2] [3] According to the 'protein only' hypothesis developed by Prusiner, 4 the infectious agent is the PrPsc protein and the propagation of this abnormal isoform is ascribed to the conversion of PrPc into PrPsc under the influence of PrPsc. The cellular site where this conversion takes place remains unclear. One of the hypotheses is that the conversion of PrPc occurs at the plasma membrane. 2 Whatever the cellular site of conversion, the cellular form PrPc is both essential for the propagation of the infectious agent and for the development of the disease and neuropathology. Moreover, mice which do not express PrPc because of disruption of their prion gene, are viable 5 and resistant to scrapie. [6] [7] [8] The cellular isoform PrPc is a glycosylphosphatidylinositol (GPI)-anchored cell surface sialoglycoprotein expressed in the CNS but also in extra-cerebral tissues such as heart, lung, kidney 9, 10 and in blood cells. 11 Indeed, the PrPc protein is detected at the cell surface of platelets, 12, 13 lymphocytes and monocytes. [14] [15] [16] [17] [18] [19] [20] [21] On the other hand, the presence of PrPc is not shown on the surface of erythrocytes or granulocytes by these authors.
PrPc is present on CD34 + multipotential bone marrow stem cells. 17 PrPc is also expressed at different levels on mature blood cells depending on the cell type. Indeed, lymphocytes, monocytes, NK cells and platelets are blood cells which express high levels of PrPc at their surface, whereas granulocytes and red blood cells are those with lower or undetectable amounts of PrPc at their plasma membrane. [15] [16] [17] [18] [19] 22 Furthermore, PrPc expression differs between these cell subsets. T cells and NK cells express the same amount of PrPc, but more than B cells. 18, 19 There is also an activation-dependent PrPc expression in human blood cells. Activated T cells express higher PrPc levels than their resting counterparts or than NK cells. 15, 16, 18 Monocytes stimulated with IFN␥ up-regulate PrPc expression. 18 Finally, activated platelets express more PrPc at their surface than resting platelets. 12, 13, 19 These results show that PrPc expression can be regulated by cell activation. All the data described here suggest that PrPc expression on human hematopoietic cells can be modulated by the activation and developmental status of these cells.
The properties of retinoids and particularly of ATRA have led to the development of therapies for the prevention or treatment of various pathologies. 23 ATRA has been shown in vivo [24] [25] [26] to induce complete remissions in patients affected by acute promyelocytic leukemia (APL), through differentiation of the leukemia cells. 27 In vitro, it also induces differentiation of human leukemia cell lines. 28 PrPc has been identified at the membrane level of the human myeloid leukemia cell line HL60 which, upon ATRA treatment, can be differentiated into granulocytic cells. 17 These authors have shown that both PrPc mRNA and protein expression are down-regulated upon granulocyte differentiation of HL60 cells.
In order to assess whether the down-regulation of prion protein expression is a consequence of cell maturation or a direct ATRA regulation, we have studied the expression of PrPc mRNA and protein in the APL cell line NB4 29 and in both retinoid-sensitive and -resistant sublines. [30] [31] [32] These cell lines (NB4, NB4-R1 and NB4-R2) constitute an appropriate cell system for in vitro analysis of gene regulation and phenotypic changes associated with granulocytic maturation. NB4, NB4-R1 and NB4-R2 cells carry the t(15;17) translocation which creates the PML-RAR fusion gene between the carboxy-terminus of the RAR␣ and the amino-terminal region of the PML gene. 33, 34 The fusion protein PML-RAR␣ exerts a dominantnegative effect on RAR␣-dependent transcription. The NB4 cell line is maturation-responsive to ATRA, 29 whereas NB4-R1 and NB4-R2 sublines display no maturation in the presence of ATRA. 31, 32 In NB4-R1 cells, resistance to maturation is not an unresponsiveness to ATRA, because cells do respond to ATRA in becoming competent to undergo terminal maturation. 31 In contrast, NB4-R2 cells are clearly unresponsive to ATRA because of the mutation of Gln903 to an in-phase stop codon in the ligand-binding domain of PML-RAR␣. 32 The mutated form PML-RAR␣⌬903 unable to bind ATRA, exerts a dominant-negative effect on transactivation properties of wild-type RAR␣ and PML-RAR␣.
Our results show that (1) PrPc mRNA is down-regulated upon ATRA treatment earlier than in HL60 cells; (2) this down-regulation is dependent on protein factor(s); (3) the PrPc mRNA down-regulation is correlated with that of the cell surface PrPc expression; (4) ATRA can down-regulate membrane prion protein expression independently of the process of granulocyte maturation.
Materials and methods

Cell lines and culture conditions
The NB4 human APL cell line, 29 its maturation-resistant forms NB4-R1 30, 31 and NB4-R2 31,32 established in our laboratory and the U-937 histiocytic lymphoma cell line, were maintained in RPMI-1640 medium (Gibco-BRL, Life Technologies, Cergy-Pontoise, France) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin and 50 g/ml streptomycin (Gibco-BRL, Life Technologies). HL60 cell line was grown in the same medium supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL, Life Technologies). The different cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO 2 . Cell density was assessed with an electronic particle counter and size analyzer (Beckman Coulter Electronics, Roissy, France). ATRA and cycloheximide (CHX) both purchased from Sigma (St Louis, MO, USA), were used respectively at the final concentrations of 1 M 29 and 10 g/ml. [35] [36] [37] This CHX concentration causes more than 90% inhibition of protein synthesis. 36 Nevertheless, at this concentration of CHX, the cells were viable and the proliferation was not affected as it was measured by the WST-1 colorimetric assay (Roche Molecular Biochemicals, Indianapolis, IN, USA). Cell cultures were diluted with fresh culture medium every 48 h and ATRA concentration was adjusted if necessary to remain unchanged. Evaluation of morphological maturation was performed on cytospin smears stained with May-Grü nwald-Giemsa (MGG).
Antibodies
Anti-prion monoclonal antibody (mAb) 3F4 which recognizes both PrPc and PrPsc 38 was purchased from Clinisciences (Montrouge, France). The specificity of this mAb has been extensively checked by several laboratories. 12, [16] [17] [18] [19] 39 Mouse mAb raised against the human CD11c subunit of the p150.95 integrin was supplied by Dako (Carpenteria, CA, USA ) and pelleted by centrifugation at 1200 g for 10 min at 4°C. Cell pellets were resuspended in PBS + supplemented with 1 × protease inhibitor cocktail (PIC) purchased from Sigma, in order to have a concentration of cells of 1.5 × 10 7 cells/ml. Cells were then lysed in a nitrogen cavitation under a pressure of 60 bars for 30 s. After addition of 1 mM phenylmethylsulfonylfluoride (PMSF) purchased from Sigma, nuclear proteins were pelleted by centrifugation at 1200 g for 10 min at 4°C. Membrane proteins were collected by centrifugation at 12 000 g for 20 min at 4°C. The proteins were extracted in PBS + −0.2 M octyl ␤-glucoside (Sigma) and proteases inhibitors for 1 h 30 min. Membrane proteins were collected after centrifugation at 12 000 g for 20 min at 4°C. Proteins concentrations were determined using the Micro BCA Protein Assay Reagent Kit (Pierce, Rockford, IL, USA).
Western blot analysis
Membrane protein extracts were boiled in the presence of 5% ␤-mercapto-ethanol and resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) on 12% acrylamide mini-slab running gels under denaturing conditions, according to Laemmli's procedure. 40 Molecular mass markers were purchased from BioRad (Hercules, CA, USA). The separated polypeptides were electrotransferred on to polyvinylidene difluoride (PVDF) membranes (Immobilon-P; Millipore, Bedford, MA, USA) at 60 V for 1 h at 4°C in 10 mM (cyclohexylamino)-1-propane sulfonic acid pH 10.7 (Caps buffer). The blots were saturated overnight at 4°C with PBS + supplemented with 5% non-fat milk, then washed five times in PBS + containing 0.5% Tween 20 (PBS-Tween) and incubated at room temperature for 2 h with the mAb 3F4 at 1:50 000 or 1:10 000 dilution in PBS-Tween. The immunoblots were washed five times in PBS-Tween and incubated at room temperature for 45 min with a HRP-coupled goat antimouse Ig secondary Ab at 1:10 000 dilution in PBS-Tween. The blots were then washed five times in PBS-Tween and revealed using the enhanced chemiluminescence (ECL) reagents (Amersham, Les Ulis, France). A control experiment with the HRP-coupled goat anti-mouse Ig secondary Ab alone was run to ascertain specificity of its binding. 
Quantitative flow cytofluorometry analysis
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Amplification and subcloning of human prion and actin probes
A human prion cDNA fragment kindly given by Dr Dormont was used for prion amplification by polymerase chain reaction (PCR). Synthesized primers (Genset Oligos) used for the PCR reaction had the following sequences: hamster prion forward 5Ј-CACAATCAGTGGAACAAGCC-3Ј, reverse 5Ј-TCTTCCAT CGTAGTAGGCCT-3Ј. 1 These primers were designed to generate a fragment of 456 bp which was obtained after 30 cycles of PCR at the hybridization temperature of 57°C for 30 s. The amplified fragment was subcloned in pGEM-T Easy vector (Promega, Madison, WI, USA). The sequence of the cloned fragment has been verified (Act Gene; Euro Sequence Gene Services, Evry, France).
For the amplification of the ␤-actin probe, total RNA extracted of NB4 cells was reverse-transcribed to complementary desoxyribonucleic acid (cDNA). The ␤-actin primer pair (Promega) used for the PCR reaction had the following sequences: ␤-actin forward 5Ј-TCATGAAGTGTGACGTTGA-CATCCGT-3Ј, reverse 5Ј-CCTAGAAGCATTTGCGGTGCAC-GATG-3Ј. These primers were designed to generate a fragment of 285 bp which was obtained after 40 cycles of PCR at the hybridization temperature of 65°C for 1 min. The amplified fragment was subcloned in pGEM-T Easy vector (Promega).
RNA isolation and Northern blot analysis
Cultured cells were lysed by Trizol reagent (Gibco BRL, Life Technologies) and RNA were extracted according to the method developed by Chomczynski and Sacchi. 41 Total RNA (20 g per lane) were denatured, resolved on a 1.1% agarose gel containing 3-(N-morpholino)-2-hydroxypropanesulfonic acid (MOPS) pH 7 and formaldehyde, washed in 20 × SSC for 1 h and transferred overnight to a Hybond N nylon membrane (Amersham) in 20 × SSC buffer. After pre-hybridization in a solution containing 0.5 M phosphate buffer (Na 2 HPO 4 /NaH 2 PO 4 ) pH 7.2, 7% SDS and 200 g/ml denatured salmon sperm DNA at 65°C, the blot was hybridized overnight to 2 × 10 6 c.p.m./ml of the appropriate random primed ␣-32 P-labeled probes (Prime-a-gene; Promega) at 65°C in the same buffer. Blot was then washed and exposed on a Kodak X-OMAT AR film. Autoradiograms were analyzed by scanning densitometry using the Multi-Analyst software.
Ribonuclease (RNase) protection assays
The plasmid containing the prion probe was linearized by the restriction enzyme SacII. As the linearization generated 3Ј overhang ends, the plasmid was incubated for 15 min at 22°C with DNA polymerase I large fragment (Klenow) purchased from Promega. ␣-32 P-UTP-labeled probes (prion and the L32 and glyceraldehyde-phosphate-dehydrogenase or GAPDH controls purchased from Pharmingen) were prepared using reagents from the RiboProbe In Vitro Transcription system SP6/T7 (Promega) and RiboQuant Ribonuclease Protection Assay (Pharmingen) kits. These probes were used for RNase protection studies, following the standard protocol described by the manufacturer (Pharmingen). Briefly, 20 g of total RNA were hybridized to the labeled anti-sense RNA probes, after which free probes and other single-stranded RNA are digested with RNases. The remaining 'RNase-protected' probes were purified and resolved on denaturing 5% polyacrylamide gels which were exposed on Kodak X-OMAT AR films. Autoradiograms were quantified by scanning densitometry using the Multi-Analyst software.
Immunofluorescence staining and confocal analysis NB4, NB4-R1 and NB4-R2 cells cultured in the presence or absence of ATRA were collected and washed three times in PBS. They were then incubated on ice for 45 min either with the mAb 3F4 or with an anti-human CD11c Ab at 1:50 and 1:20 dilutions in PBS-1% bovine serum albumin (BSA), respectively. After three washes in PBS-1% BSA, cells were incubated on ice in the dark for 45 min with a FITC-conjugated goat anti-mouse Ig secondary Ab at 1:200 dilution in PBS-1% BSA. After two washes in PBS-1% BSA and one in PBS, cells were spun on to glass slides using a cytocentrifuge and mounted in Vectashield containing DAPI and antifade solution. Slides were examined by confocal laser scanning microscopy using a BioRad MRC-1024 confocal imaging system (BioRad Microscience, Hertfordshire, UK) and an inverted Diaphot 300 Nikon microscope. Images were collected using an oil immersion lens (60×, NAI.4 plan Apochromat). For FITC excitation, a krypton/argon ion laser (Ion Laser Technology, Salt Lake City, UT, USA) was used at the 488 nm wavelength. FITC images were digitized to obtain pseudocolored green. Each image represents a single section for which the confocal system was adjusted to allow a field depth of about 0.8 m. Two controls were performed: (1) incubation of cells with the buffer alone; and (2) incubation of cells with the FITC-conjugated goat anti-mouse Ig secondary Ab alone.
Results
Cellular prion protein PrPc expression at the surface of human blood cell lines
We detected PrPc surface immunoreactivity on human cell lines using the mAb 3F4 (Figure 1 ). The epitope recognized by the mAb 3F4 was present on all the cell lines studied. We can nevertheless notice a difference in PrPc glycoforms expression. While the three PrPc forms seem to be expressed on NB4, NB4-R1 and NB4-R2 membranes, HL60 cells only express a high molecular mass form which could correspond to the diglycosylated form of PrPc. 42, 43 The U-937 cell line exhibits an important expression of PrPc which confirms that monocytic cells express PrPc at their surface with a higher level than other blood cells. [14] [15] [16] [17] [18] [19] Human leukemia cell line surface immunoreactivity for the mAb 3F4 was also analyzed and measured by quantitative
Figure 1
Western blot analysis of membrane cellular prion protein PrPc extracted from human blood cell lines. Cultured cells were lysed and 15 g of membrane protein extracts were resolved by SDS-PAGE 12% gel and detected using the mAb 3F4. flow cytofluorometry (Figure 2 ). Fluorescence histograms of stained leukemia cell lines exhibited a monophasic distribution. NB4 cells and its sublines NB4-R1 and NB4-R2 express more PrPc at their plasma membrane than HL60 cells. 
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Kinetic of PrPc mRNA expression in NB4 cells treated with ATRA
We examined the level of mRNA for the prion protein by Northern blot. NB4 cells were differentiated with ATRA and harvested for total RNA extraction after 24, 48, 72 and 96 h. PrPc mRNA was drastically down-regulated as early as 24 h after treatment with ATRA, while the level of ␤-actin mRNA remained approximately constant (Figure 3a) . Since ATRA treatment of NB4 cells leads to the regulation of several genes involved in the differentiation process, down-regulation of prion mRNA expression seems to correlate with granulocyte maturation. The autoradiograms were analyzed by scanning densitometry (Figure 3b) . The results were consistent with the ones obtained on the Northern blot as described above (Figure 3a) . 
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Early down-regulation of PrPc mRNA expression in NB4 cells treated with ATRA
To further investigate PrPc gene regulation by short ATRA treatment, PrPc mRNA was analyzed by RNase protection assay. NB4 cells were treated with ATRA and harvested for total RNA extraction after 1, 2, 4, 6, 8, 12 and 24 h. A slight decrease in the level of PrPc mRNA was detected between 4 h and 6 h of treatment, but the lowest expression level of PrPc mRNA was observed after 8 h of exposure to ATRA (Figure 4a) . The autoradiogram was analyzed by scanning densitometry (Figure 4a ) and the results were consistent with the ones obtained on the RNase protection experiment as described above (Figure 4a ). This experiment has been confirmed by Northern blot.
Figure 4
The protein synthesis inhibitor cycloheximide (CHX) inhibits ATRA-induced down-regulation of PrPc mRNA. Total RNA were prepared from NB4 cells either untreated or treated with ATRA (a) and/or CHX (b) for the indicated times, blotted with radioactively labeled prion and control probes (L32 and GAPDH, used as the invariant internal controls for calibration) and submitted to the RNase protection analysis. Lane p corresponds to the nondigested probes, lane c represents yeast tRNA hybridized with radioactively labeled prion and control probes, lines point to the smaller gene expression-indicative fragments after hybridization and RNase treatment (protected fragments). Autoradiograms were analyzed by scanning densitometry using the Multi-Analyst software. Each value represented on the ordinate axis is the result of the normalization of prion signal by the control (L32 and GAPDH) signals.
Protein factor(s) are involved in prion mRNA expression
We tested the effect of the protein synthesis inhibitor CHX on the expression of prion mRNA in NB4 cells. NB4 cells were treated for 8 h with either CHX, ATRA or simultaneously with ATRA and CHX. Treatment of NB4 cells with CHX resulted in an abrogation of the ATRA-induced down-regulation of PrPc mRNA at 8 h after treatment (Figure 4b ). Similar results were observed when NB4 cells were treated with both ATRA and CHX. These results indicate that the down-regulation of prion mRNA expression requires de novo protein synthesis. The autoradiograms were quantified by scanning densitometry (Figure 4b) . The results were consistent with the ones obtained
Figure 5
Down-regulation of surface cellular prion protein PrPc in NB4 cells treated with ATRA. Cells were cultured in the presence or absence of ATRA for 48 h and 96 h, lysed and 10 g of membrane protein extracts were resolved by SDS-PAGE 12% gel and detected using the mAb 3F4.
on the RNase protection experiment as described above (Figure 4b ).
The regulation of prion mRNA expression is correlated with a decrease in surface prion protein immunoreactivity
In order to elucidate if prion mRNA expression decrease was associated with a decrease at the prion protein level, we extracted membrane proteins from NB4 cells treated 48 h and 96 h by ATRA, electrophoresed and blotted them with the mAb 3F4. We observed a largest decline in surface prion protein immunoreactivity occurring after the first 48 h of treatment by ATRA ( Figure 5 ). These results show a strong association between decreased prion mRNA and decreased surface PrPc immunoreactivity.
The down-regulation of membrane prion protein expression is not associated with ATRA-induced granulocyte maturation
Indirect immunofluorescence staining was performed in order to assess a possible relationship between the down-regulation of surface prion protein PrPc and granulocyte maturation. NB4, NB4-R1 and NB4-R2 cells were treated with ATRA for 96 h and stained either with the mAb 3F4 (Figure 6b , e and h) or with an Ab raised against the human CD11c subunit of the p150.95 integrin (Figures 6c, f and i) . We observed a decrease in membrane prion protein expression in NB4 cells treated with ATRA vs to the untreated cells (Figure 6b) . In maturation-resistant NB4-R1, we also observed a large decrease in the expression of membrane prion protein after 96 h of treatment by ATRA (Figure 6e ). In contrast, no significant variation of surface prion protein expression in NB4-R2 cells upon ATRA treatment was observed (Figure 6h) . The morphological features of NB4, NB4-R1 and NB4-R2 cells in response to ATRA treatment can be observed in Figures 6a, d and g, respectively. Contrary to the ATRA-treated NB4 cells, which exhibited morphologic characteristics of granulocyte maturation as variations of the nucleus shape (reniform or bilobed), a clear and pale stained cytoplasm (Figure 6a ), NB4-R1 and NB4-R2 cell lines showed no morphological changes upon ATRA treatment (Figures 6d and g ). The differentiation process was also followed by expression of the cell surface antigen CD11c integrin. As expected, ATRA induced a strong
Leukemia
Figure 6
Down-regulation of membrane cellular prion protein by ATRA is independent of granulocyte maturation. Untreated (left panels) or treated cells (right panels) were stained with May-Grü nwald-Giemsa (a, d, g ), the mAb 3F4 and FITC-conjugated goat antimouse Ig secondary Ab (b, e, h), the anti-CD11c and FITC-conjugated goat anti-mouse Ig secondary Ab (c, f, i).
expression of CD11c in NB4 cells while it failed to increase this marker in NB4-R2 cells (Figures 6c and i) . Since NB4-R1 cells do respond to ATRA whereas NB4-R2 cells do not, our results strongly suggest that the down-regulation of membrane prion protein is due to a direct effect of ATRA rather than to the maturation process.
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Dose-dependent effect of ATRA on PrPc mRNA expression
A down-regulation of PrPc mRNA and protein expression is observed in NB4 cells treated with 10 −6 M ATRA and cells matured into granulocytes. Since we have shown that the down-regulation of PrPc expression is a direct effect of ATRA, we tested doses higher or equal to physiological concentrations of ATRA, on the expression of PrPc mRNA by RNase protection assay, in order to demonstrate a dose-dependent effect of this agent (Figure 7) . The expression of PrPc mRNA decreased between 10 −8 M and 10 −6 M. The main effect was observed at the highest concentration of ATRA (10 −6 M). The autoradiogram analyzed by scanning densitometry (Figure 7b ) gave results consistent with the ones obtained on the RNase protection experiment as described above (Figure 7a ).
Discussion
Many reports have shown that PrPc is expressed in several tissues and particularly in blood cells. 11 The presence of cellular prion protein in hematopoietic system is important to consider because this system could play a pivotal role in the propagation of the infectious agent. 44 Blood cells express PrPc at different levels depending on the cell type. Among the blood cells, granulocytes are those with the lower expression or undetectable amounts of PrPc at their surface. 14, [16] [17] [18] [19] The presence of PrPc in granulocytes is still unclear. 39, 45 These conflicting results can be explained by the sensitivity of the assays used. Diomede and colleagues 45 used immunoprecipitation and reverse transcription-polymerase chain reaction (RT-PCR) assays to detect PrPc expression in neutrophils. These assays enable enrichment of prion mRNA and protein. Using these assays, they succeeded in detecting PrPc in granulocytes. Dü rig and colleagues 39 observed a difference of plasma membrane PrPc expression between granulocytes from patients affected by paroxysmal nocturnal hemoglobinuria or PNH (which is a pathology characterized by a deficiency of GPI-linked cell surface proteins) and normal granulocytes. This cellular model is appropriate to show low but significant differences of PrPc expression. Indeed, these experiments demonstrated an absence of PrPc staining in PNH granulocytes compared with normal granulocytes. Concerning our results, we observed, by flow-cytofluorometry, low but significant amounts of PrPc at the surface of NB4 cells of granulocyte lineage compared with promonocyte U-937 cells (Figure 1) .
Using HL60 cells treated with ATRA, Dodelet and Cashman 17 have shown a down-regulation of prion protein expression. These authors suggested that this decline of PrPc expression is concomitant with the differentiation process of HL60 cells. Indeed, under ATRA treatment, these cells become granulocytic cells and express a low level of cellular prion protein as granulocytes. Little information is presently available concerning the regulation of the prion gene expression except for neuronal cells. 46, 47 The purpose of this work was to evaluate the effects of ATRA on the regulation of prion gene expression in hematopoietic cells lines, dependently or independently of the granulocytic maturation process. We have chosen the NB4 cell system 29 with its maturation-resistant subclones, [30] [31] [32] which offer the possibility to study granulocytic maturation under ATRA treatment.
Our results show a down-regulation of PrPc mRNA expression after treatment of NB4 cells by ATRA. The pro-
Figure 7
Dose-dependent effect of ATRA on PrPc mRNA expression. Total RNA were prepared from NB4 cells either untreated or treated with ATRA for 48 h at the indicated concentrations, blotted with radioactively labeled prion and control probes (L32 and GAPDH, used as the invariant internal controls for calibration) and submitted to the RNase protection analysis. Lane p corresponds to the nondigested probes, lane c represents yeast tRNA hybridized with radioactively labeled prion and control probes, lines point to the smaller gene expression-indicative fragments after hybridization and RNase treatment (protected fragments). Autoradiogram was analyzed by scanning densitometry using the Multi-Analyst software. Each value represented on the ordinate axis is the result of the normalization of prion signal by the control (L32 and GAPDH) signals.
moter of the prion gene contains multiple copies of GC rich repeats similarly observed in 'housekeeping' genes and is devoid of TATA box. These GC-rich sequences represent a motif, which may function as a canonical binding site for the transcriptional factor Spl. Nevertheless, no consensus binding sequences for RAR (retinoic acid-responsive elements or RARE) have yet been found in the prion promoter gene. 1, 48, 49 The down-regulation of prion gene could not be directly mediated by ATRA. We demonstrated that PrPc mRNA is down-regulated as early as 8 h after treatment of NB4 cells by ATRA (Figure 4a ). This regulation is earlier than it has been observed in HL60 cells. 17 The time-course of the modulation of the prion transcript expression favors the hypothesis that prion gene might not be a direct target of ATRA, that we checked by studying the effect of CHX on the expression of prion mRNA. CHX affecting the ATRA-repressed level of the transcript coding for PrPc (Figure 4b ), demonstrated that synthesis of one or more protein factor(s) is necessary for the regulation of prion mRNA expression.
In the present work, we show a down-regulation of membrane prion protein expression during ATRA treatment of maturation-resistant NB4-R1 cells that are responsive to ATRA. 31 On the contrary, the same phenomenon was not observed in ATRA-treated NB4-R2 cells that neither display maturation nor response to ATRA. Indeed, NB4-R2 cells express a mutated form of PML-RAR ␣ unable to bind ATRA. 32 These results demonstrate that in the human promyelocytic leukemia cell line NB4, there is a dissociation between the down-regulation of membrane prion protein expression and the process of granulocyte maturation. Furthermore, our data suggest that the modulation of prion protein expression observed upon ATRA treatment is only due to an ATRA effect via the RAR␣. This effect of ATRA has already been observed on telomerase expression. In NB4 cells, ATRA also downregulates telomerase expression, in a pathway independent of cell maturation. 50 We do not know whether the regulation is transcriptional or post-transcriptional. Indeed, we cannot exclude a destabilization of PrPc mRNA even if no sequences of alternative polyadenylation has been described in humans. 51 At least two mechanisms for down-regulation of PrPc mRNA could exist. Either ATRA directly induces a repressor that binds prion gene promoter (transcriptional regulation) or a factor that decreases its mRNA life span (post-transcriptional regulation). Alternatively, in cascade, ATRA could induce an activator that induces a repressor itself.
We show that prion gene expression can be regulated by ATRA in the NB4 leukemia cell line. However, the relevance of this finding to normal hematopoietic cells remains to be elucidated. Similarly, further studies are needed to determine the potential benefits of ATRA on PrPc expression in neuronal cells of patients suffering from CJD. If PrPc can be diminished in patients without deleterious effects as is the case for Prnp 0/0 mice, 5 then reducing the level of PrPc mRNA with ATRA might represent an effective attempt at substantially slowingdown prion disease progression in incipient cases of spongiform encephalopathies, for example in delaying the onset of CNS symptoms and signs. Moreover, the fact that Prn-p 0/+ heterozygous mice show longer scrapie incubation times than their wild-type counterparts 6, 8 argues that disease progression may be rate-limited by PrPc concentration.
